[Diagnosis and therapy of rhabdomyosarcoma in children]

Area of Science:

• Pediatric Oncology
• Cancer Research

Context:

• Rhabdomyosarcoma (RMS) is a rare pediatric soft tissue sarcoma.
• The S.I.O.P.-89 protocol aimed to standardize and improve RMS treatment outcomes.
• Previous treatment regimens had lower survival rates.

Purpose:

• To analyze the 24-month relapse-free survival in pediatric patients with rhabdomyosarcoma (RMS) treated under the S.I.O.P.-89 protocol.
• To evaluate the efficacy of the S.I.O.P.-89 protocol compared to earlier treatment approaches.
• To establish diagnostic and examination recommendations for RMS suspects.

Summary:

• The study analyzed 62 patients with rhabdomyosarcoma (RMS) using the S.I.O.P.-89 protocol.
• Relapse-free survival rates at 24 months were 100% for stage I, 90% for stage II, and 62% for stage III RMS.
• These survival rates represent a doubling compared to patients treated before 1993.
• Diagnoses utilized a comprehensive approach including clinical, radiological, and morphological data.
• Common RMS sites included the retroperitoneal space, perineum, bladder, and thoracic cavity.

Impact:

• The S.I.O.P.-89 protocol has demonstrably improved survival outcomes for pediatric rhabdomyosarcoma.
• The findings support the effectiveness of current treatment strategies for RMS.
• Standardized diagnostic recommendations can enhance early detection and management of RMS.